DBV Technologies (DBVT) Free Cash Flow (2020 - 2026)
DBV Technologies (DBVT) posted Free Cash Flow of -$53.0 million for Q2 2026, down 7.07% sequentially from -$49.5 million in Q1 2026, and down 56.34% YoY from -$121.4 million in Q2 2025.
DBV Technologies (DBVT) Free Cash Flow (2020 - 2026) Analysis & Trends
DBV Technologies has reported Free Cash Flow for 7 years, with the latest figure at -$53.0 million in Q2 2026.
- Quarterly Free Cash Flow fell 56.34% year-over-year to -$53.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$170.6 million (down 92.61% YoY) and the FY2025 annual result came in at -$121.7 million, down 13.95% from the prior year.
- Free Cash Flow eased to -$53.0 million in Q2 2026 per DBVT's latest filing, from -$49.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$1.6 million in Q1 2022 and troughed at -$53.0 million in Q2 2026.
- A 5-year average of -$26.0 million and a median of -$23.4 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 95.56% in 2022, then slumped 1198.14% in 2023.
- Over 5 years, Free Cash Flow stood at -$23.9 million in 2022, then surged by 41.26% to -$14.0 million in 2023, then increased by 13.61% to -$12.1 million in 2024, then plunged by 193.11% to -$35.5 million in 2025, then tumbled by 49.1% to -$53.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$53.0 million, -$49.5 million, and -$35.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | -53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.00 Mn |
| Jun 30, 2026 | -53.00 Mn |
| Mar 31, 2026 | -49.50 Mn |
| Mar 31, 2026 | -49.50 Mn |
| Dec 31, 2025 | -35.55 Mn |
| Dec 31, 2025 | -35.55 Mn |
| Sep 30, 2025 | -32.57 Mn |
| Sep 30, 2025 | -32.57 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Jun 30, 2025 | -33.90 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Dec 31, 2024 | -12.13 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -35.81 Mn |
| Jun 30, 2024 | -35.81 Mn |
| Mar 31, 2024 | -36.03 Mn |
| Mar 31, 2024 | -36.03 Mn |